文献速递中医内科中药与中成药合理使用

复方苦参注射液治疗食管癌的临床疗效与机制:网状Meta分析与体外实验

Investigation on the clinical efficacy and mechanism of compound kushen injection in treating esophageal cancer based on multi-dimensional network meta-analysis and in vitro experiment.
PubMed 文献 · J Ethnopharmacol · 2021-07-03

本研究采用网状Meta分析评价抗肿瘤中药注射剂治疗食管癌的疗效与安全性,并联合体外实验探索复方苦参注射液的作用机制。结果显示,复方苦参注射液联合化疗在总临床有效率、生活质量改善及恶心呕吐减少方面的累积排序概率面积分别为89.1%、81.8%和92.4%,被确定为优势品种;体外实验表明其可抑制食管癌细胞增殖并下调EGFR和AURKA的mRNA及蛋白过表达。

要点

  • 复方苦参注射液联合化疗在总临床有效率、生活质量及减轻恶心呕吐方面排序居前。
  • 复方苦参注射液被确定为治疗食管癌的优势中药注射剂品种。
  • 其机制可能与下调EGFR和AURKA的mRNA及蛋白过表达、抑制细胞增殖有关。

核心结论

  • 网状Meta分析确认复方苦参注射液对食管癌有疗效,且优于其他抗肿瘤中药注射剂。
  • 复方苦参注射液通过调控EGFR和AURKA的异常表达抑制食管癌细胞增殖。

研究设计与样本

  • 检索多个电子数据库至2020年9月5日,纳入中药注射剂治疗食管癌的随机对照试验进行网状Meta分析。
  • 使用WinBugs和Stata软件计算总临床有效率、生活质量改善及不良反应等结局指标。
  • 采用累积排序概率面积和三维聚类分析对中药注射剂各结局的疗效与安全性排序。
  • 体外实验用CCK-8法观察复方苦参注射液对食管癌细胞增殖的影响。
  • 用RT-qPCR和Western Blot检测ESCA细胞中EGFR和AURKA的mRNA及蛋白表达。

主要发现

  • 复方苦参注射液联合化疗在总临床有效率的累积排序概率面积为89.1%。
  • 复方苦参注射液联合化疗在生活质量改善的累积排序概率面积为81.8%。
  • 复方苦参注射液联合化疗在减少恶心呕吐的累积排序概率面积为92.4%。
  • 复方苦参注射液被确定为治疗食管癌的优势品种,可抑制食管癌细胞增殖。
  • 复方苦参注射液可下调EGFR和AURKA的mRNA及蛋白过表达。

临床怎么用

  • 对于食管癌患者,可考虑复方苦参注射液联合化疗以提升总临床有效率。
  • 复方苦参注射液联合化疗可能有助于改善生活质量和减少恶心呕吐。
  • 其作用机制涉及下调EGFR和AURKA表达,可作为机制解释参考。

局限性

  • 网状Meta分析的检索截止时间为2020年9月5日,未纳入此后发表的随机对照试验。
  • 体外实验结果不能直接等同于临床疗效,机制结论需进一步体内研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Esophageal cancer, as a high incidence of gastrointestinal cancer, has an indelible impact on human life and health. The combination of Chinese herbal injections and chemotherapy is commonly applied in the treatment of Esophageal cancer. AIM OF THE STUDY: This study aimed to confirm the clinical advantage of Compound Kushen Injection to treat esophageal cancer and explore its molecular mechanism. METHODS: The network meta-analysis method was used for the clinical evaluation of anti-tumor Chinese herbal injections. Initially, several electronic databases were searched to identify randomized controlled trials regarding Chinese herbal injections to treat esophageal cancer from their inception to September 5, 2020. Then, WinBugs and Stata software was used to calculate and analyze the outcome indicators, including total clinical efficiency, improvement of quality of life and adverse reactions. Furthermore, the surface under the cumulative ranking curve and three-dimensional cluster analysis were used to rank the efficacy and safety of Chinese herbal injections about each outcome. Cell Counting Kit-8 assay was used to observe the effect of Compound Kushen Injection on the proliferation of esophageal cancer cells. Real-Time Quantitative PCR and Western Blot analysis were used to detect the mRNA and protein expression of EGFR and AURKA in ESCA cells. RESULTS: The surface under the cumulative ranking curve of Compound Kushen Injection combined with chemotherapy in total clinical efficiency, quality of life, reduction of nausea and vomiting were ranking at 89.1%, 81.8% and 92.4%, respectively. Compound Kushen Injection was determined as the dominant variety in the treatment of esophageal cancer which can inhibit the proliferation of esophageal cancer cells and downregulate the overexpression of EGFR and AURKA mRNA and protein. CONCLUSION: In this study, network meta-analysis was applied to confirm that Compound Kushen Injection has a curative effect on esophageal cancer and is superior to other anti-tumor Chinese herbal injections. Combined with the network pharmacology and in vitro experiment, the mechanism of Compound Kushen Injection inhibiting the proliferation of esophageal cancer cells by regulating the abnormal expression of EGFR and AURKA was revealed.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhou W, Huang Z, Wu C, et al. Investigation on the clinical efficacy and mechanism of compound kushen injection in treating esophageal cancer based on multi-dimensional network meta-analysis and in vitro experiment. J Ethnopharmacol. 2021. PMID: 34224810. doi:10.1016/j.jep.2021.114386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。